ALZpath and Alamar Biosciences have expanded their strategic agreement to include clinical diagnostics for Alzheimer’s disease, granting Alamar commercial rights to utilize the proprietary pTau217 antibody in blood-based diagnostic tests intended for clinical use, according to the companies. The broadened collaboration follows an initial agreement from February 2024 that integrated the antibody into research use only assays.
The expanded partnership allows Alamar, its customers, and its collaborators to develop in vitro diagnostic (IVD) assays using the proprietary pTau217 antibody. According to ALZpath CEO Mike Banville, this step aims to make blood-based Alzheimer’s disease testing more accessible to clinicians and patients worldwide.
“As adoption of pTau217 continues to accelerate worldwide, we remain focused on enabling our partners to deliver clinically validated diagnostic solutions that provide earlier answers and support better patient care,” Banville stated in a release.
Global Momentum for Alzheimer’s Biomarkers
The announcement coincides with the Association for Diagnostics and Laboratory Medicine Annual Meeting, an event where the adoption of blood-based Alzheimer’s biomarkers serves as a central theme. Momentum for these biomarkers was also highlighted earlier this month at the Alzheimer’s Association International Conference. At that conference, more than 140 presentations and posters featured data from assay panels incorporating the ALZpath antibody.
Did you know? Over 140 presentations and posters at the recent Alzheimer’s Association International Conference featured data from assay panels that use the ALZpath antibody.
Detecting and Monitoring Disease Progression
According to the companies, utilizing the antibody in various blood-based tests is intended to assist in how Alzheimer’s disease is detected, treated, and monitored. Licensing the technology to industry leaders and laboratories is designed to provide scalable testing options to clinicians and patients alike.
Pro Tip for Laboratory Professionals
Frequently Asked Questions
What is the main goal of the expanded ALZpath and Alamar Biosciences agreement?
The agreement grants Alamar commercial rights to use ALZpath’s proprietary pTau217 antibody in blood-based diagnostic tests intended for clinical use, aiming to make Alzheimer’s testing more accessible.
When did the two companies begin their partnership?
The companies initially entered a strategic agreement in February 2024 to integrate the antibody into research use only assays.
Where was the announcement made?
The announcement is being made during the Association for Diagnostics and Laboratory Medicine Annual Meeting.
Stay Informed on Clinical Diagnostics
Worth a look